Cargando…

Activating HER2 mutations as emerging targets in multiple solid cancers

The epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases activates signalling pathways regulating cellular proliferation and survival. HER2 is a non-ligand-binding member of this family and exerts its activity through heterodimerisation with other EGFR family mem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Connell, Claire M, Doherty, Gary J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708307/ https://www.ncbi.nlm.nih.gov/pubmed/29209536 http://dx.doi.org/10.1136/esmoopen-2017-000279

Ejemplares similares

Emerging Targeted Therapies for HER2-Positive Breast Cancer
por: Mercogliano, María Florencia, et al.
Publicado: (2023)

Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
por: Koirala, Nischal, et al.
Publicado: (2022)

Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
por: Yoshikawa, Ayumu, et al.
Publicado: (2022)

Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer
por: Tobias, Joshua, et al.
Publicado: (2022)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
por: Mitani, Seiichiro, et al.
Publicado: (2020)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Targeted therapy for HER2 positive breast cancer
por: Incorvati, Jason A, et al.
Publicado: (2013)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors
por: Wang, Deqiang, et al.
Publicado: (2022)

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer
por: Brufsky, Adam M
Publicado: (2014)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Activating HER3 mutations in breast cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
por: Sitia, Leopoldo, et al.
Publicado: (2022)

Cohesin Mutations in Cancer: Emerging Therapeutic Targets
por: Antony, Jisha, et al.
Publicado: (2021)

Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment
por: Parker, Brittany C., et al.
Publicado: (2013)

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
por: Correa, Isabel, et al.
Publicado: (2001)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

Analysis of different HER‐2 mutations in breast cancer progression and drug resistance
por: Sun, Zijia, et al.
Publicado: (2015)

The emerging role of CDK4/6i in HER2-positive breast cancer
por: O’Sullivan, Ciara C., et al.
Publicado: (2019)

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
por: Miles, David W
Publicado: (2009)

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
por: Hackshaw, Michelle D., et al.
Publicado: (2020)

HER3 signaling and targeted therapy in cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members
por: Olayioye, Monilola A
Publicado: (2001)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
por: Mota, Jose Mauricio, et al.
Publicado: (2017)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Targeting HER2 in breast cancer: overview of long-term experience
por: Lantz, Evan, et al.
Publicado: (2010)

Recombinant immunotoxins development for HER2-based targeted cancer therapies
por: Mahmoudi, Reza, et al.
Publicado: (2021)

Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
por: Holloway, Ryan W., et al.
Publicado: (2021)

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
por: Tarantino, Paolo, et al.
Publicado: (2021)

History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
por: Ariga, Shin
Publicado: (2023)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
por: Mohd Sharial, M. S. N., et al.
Publicado: (2012)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
por: Musolino, Antonino, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e50jvior54q0lvie2qv3lik0k6